<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Abciximab: a review and update for clinicians

Name: Abciximab: a review and update for clinicians
Keywords: Male, Dose-Response Relationship, Drug, Abciximab, Myocardial Infarction, Antibodies, Monoclonal, Coronary Angiography, Prognosis, Severity of Illness Index, Survival Analysis, Drug Administration Schedule

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 2008Publisher:Informa UK LimitedJournal:Expert Review of Cardiovascular Therapy, volume 6, pages 609-618 (issn: 1477-9072, eissn: 1744-8344,

Authors: John J. Young; Ernest L. Mazzaferri;

doi: 10.1586/14779072.6.5.609

pmid: 18510478

Abciximab: a review and update for clinicians

- Summary
- Subjects
- Metrics

Abstract

The glycoprotein (GP) IIb/IIIa receptor serves as the final common pathway of platelet-thrombus formation. Thus, the GP IIb/IIIa receptor has been identified as a target for the prevention of thrombus formation during acute coronary syndromes and/or percutaneous coronary intervention. While there are several intravenous GP IIb/IIIa inhibitors available, abciximab has proven to be a dependable agent with unique properties. Based on American College of Cardiology, American Heart Association and Society for Angiography and Interventions guidelines, compared with the other available intravenous GP IIb/IIIa inhibitors, abciximab receives the highest recommendation for use in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Abciximab is also unique in that there is no need for renal dosing and its effects are mostly reversible with platelet transfusions.

Keywords

Male, Dose-Response Relationship, Drug, Abciximab, Myocardial Infarction, Antibodies, Monoclonal, Coronary Angiography, Prognosis, Severity of Illness Index, Survival Analysis, Drug Administration Schedule, Electrocardiography, Immunoglobulin Fab Fragments, Treatment Outcome, Humans, Female, Angioplasty, Balloon, Coronary, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	8
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average